Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Consolidated revenue increased by 29.2% YoY to JPY5.1bn, with operating profit growing 25.6% YoY to JPY1.2bn.</li><li>Medical Platform business revenue rose 17.3% YoY to JPY3.2bn, with average monthly page views up 47.1% YoY.</li><li>Smart Clinic business revenue surged 70.7% YoY to JPY1.7bn, driven by new software service NOMOCa AI chat.</li></ul>

Consolidated revenue increased by 29.2% YoY to JPY5.1bn, with operating profit growing 25.6% YoY to JPY1.2bn.Medical Platform business revenue rose 17.3% YoY to JPY3.2bn, with average monthly page views up 47.1% YoY.Smart Clinic business revenue surged 70.7% YoY to JPY1.7bn, driven by new software service NOMOCa AI chat.

GENOVA  (9341 JP): 1H FY03/25 flash update

Index Rebal Trades & Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal Trades & Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Event-Driven

<ul>
<li>Quiddity's "Who is Ready" series of insights aims to objectively identify names listed on the Tokyo Stock Exchange that are potential additions to the TOPIX Index in future.</li>
<li>In October 2024, <a href="https://www.smartkarma.com/entities/celsys-inc" target="_blank" data-smartkarma-citation="entities:20774:1" rel="noopener">CELSYS (3663 JP)</a>, <a href="https://www.smartkarma.com/entities/pksha-technology-inc" target="_blank" data-smartkarma-citation="entities:26181:1" rel="noopener">PKSHA Technology (3993 JP)</a>, and <a href="https://www.smartkarma.com/entities/genova-inc" target="_blank" data-smartkarma-citation="entities:43939:1" rel="noopener">GENOVA (9341 JP)</a> were included in the TOPIX index.</li>
<li>Next, <a href="https://www.smartkarma.com/entities/wa-inc" target="_blank" data-smartkarma-citation="entities:29189:1" rel="noopener">WA Inc (7683 JP)</a> will be included in TOPIX at the end of December 2024.</li>
</ul>


Quiddity's "Who is Ready" series of insights aims to objectively identify names listed on the Tokyo Stock Exchange that are potential additions to the TOPIX Index in future.
In October 2024, CELSYS (3663 JP), PKSHA Technology (3993 JP), and GENOVA (9341 JP) were included in the TOPIX index.
Next, WA Inc (7683 JP) will be included in TOPIX at the end of December 2024.


TOPIX Inclusions: Who Is Ready (Nov 2024)

<ul>
<li>Quiddity's "Who is Ready" series of insights aims to objectively identify names listed on the Tokyo Stock Exchange that are potential additions to the TOPIX Index in future.</li>
<li>Our long-term pre-event candidate <a href="https://www.smartkarma.com/entities/celsys-inc" target="_blank" data-smartkarma-citation="entities:20774:1" rel="noopener">CELSYS (3663 JP)</a> has moved to TSE Prime. There will be a TOPIX Inclusion event on 30-Oct-24. The stock has outperformed TOPIX by 43% since <a href="https://www.smartkarma.com/insights/topix-inclusions-who-is-ready-july-2024" target="_blank" rel="noopener">July</a>.</li>
<li>
<a href="https://www.smartkarma.com/entities/pksha-technology-inc" target="_blank" data-smartkarma-citation="entities:26181:1" rel="noopener">PKSHA Technology (3993 JP)</a> and <a href="https://www.smartkarma.com/entities/genova-inc" target="_blank" data-smartkarma-citation="entities:43939:1" rel="noopener">GENOVA (9341 JP)</a> also moved to the TSE Prime market in September and will be having TOPIX Inclusion events at the end of October 2024.</li>
</ul>


Quiddity's "Who is Ready" series of insights aims to objectively identify names listed on the Tokyo Stock Exchange that are potential additions to the TOPIX Index in future.
Our long-term pre-event candidate CELSYS (3663 JP) has moved to TSE Prime. There will be a TOPIX Inclusion event on 30-Oct-24. The stock has outperformed TOPIX by 43% since July.

PKSHA Technology (3993 JP) and GENOVA (9341 JP) also moved to the TSE Prime market in September and will be having TOPIX Inclusion events at the end of October 2024.


TOPIX Inclusions: Who Is Ready (Oct 2024)

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

<ul>
<li>Post-Close on the 5th business day of October every year, the TSE announces the Free Float Weight review for all stocks where the FY ends in the Jan-March quarter.</li>
<li>Yesterday saw 210 decent changes to FFW (more up than down). There are still 400+ Phased Weight Reductions, 3 new adds (3663, 3993, 9341), and some share cancellation-based share-count reductions.</li>
<li>It turns out there is a LOT to trade. I see ¥2trln one-way (¥2trln net to buy on 245 names, and ¥2trln to sell on the other nearly 1,900 names). </li>
</ul>


Post-Close on the 5th business day of October every year, the TSE announces the Free Float Weight review for all stocks where the FY ends in the Jan-March quarter.
Yesterday saw 210 decent changes to FFW (more up than down). There are still 400+ Phased Weight Reductions, 3 new adds (3663, 3993, 9341), and some share cancellation-based share-count reductions.
It turns out there is a LOT to trade. I see ¥2trln one-way (¥2trln net to buy on 245 names, and ¥2trln to sell on the other nearly 1,900 names). 


The TOPIX October FFW Trade - BIG Numbers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/genova-inc" target="_blank" data-smartkarma-citation="entities:43939:1" rel="noopener">GENOVA (9341 JP)</a> recorded better-than-expected sales and operating profit in Q1FY25, driven by continued strong demand. With the progress achieved in Q1FY25, the company is expected to beat H1FY25 guidance.</li>
<li>Medical Platform business has been experiencing steady growth in both the number of articles and page views, leading to creation of multiple contracts and improve the platform’s unit contract price.  </li>
<li>The company had 14K customers for the Medical Platform Business and the Smart Clinic Business in Q1FY25, a mere 8% of its estimated potential customer base of 173K clinics.</li>
</ul>



GENOVA (9341 JP) recorded better-than-expected sales and operating profit in Q1FY25, driven by continued strong demand. With the progress achieved in Q1FY25, the company is expected to beat H1FY25 guidance.
Medical Platform business has been experiencing steady growth in both the number of articles and page views, leading to creation of multiple contracts and improve the platform’s unit contract price.  
The company had 14K customers for the Medical Platform Business and the Smart Clinic Business in Q1FY25, a mere 8% of its estimated potential customer base of 173K clinics.


GENOVA (9341 JP): 70% Rally Over the Last Two Months; Here’s Why Outperformance to Continue

Japan

GENOVA, Inc. operates medical platforms and smart clinics. The Company provides services for solving the problem of information asymmetry between medical institutions and users and providing a comfortable medical experience for patients by improving operational efficiency. GENOVA provides its services throughout Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GENOVA (9341 JP)

GENOVA (9341 JP): 1H FY03/25 flash update

Consolidated revenue increased by 29.2% YoY to JPY5.1bn, with operating profit growing 25.6% YoY to JPY1.2bn. Medical Platform business revenue...

Shared Research

TOPIX Inclusions: Who Is Ready (Nov 2024)

There are currently 76 names that satisfy all 5 key Segment Transfer requirements based on current data. Another 70 names can satisfy 4 out of 5...

Janaghan Jeyakumar, CFA

TOPIX Inclusions: Who Is Ready (Oct 2024)

The LONGs (Basket A) have outperformed the SHORTs (Basket B) modestly by 0.62% from 7th October to 30th October. On average, the LONGs are down...

Janaghan Jeyakumar, CFA

The TOPIX October FFW Trade - BIG Numbers

The TOPIX Buy/Sell Trade was doing OK through mid-week last week. Then on the 17th it fell hard. That was the day after 'uncertainty" on TCM (570...

Travis Lundy

GENOVA (9341 JP): 70% Rally Over the Last Two Months; Here’s Why Outperformance to Continue

GENOVA beats Q1FY25 sales and operating profit expectations and is poised to exceed H1FY25 guidance. Steady price-volume growth and potential for...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

GENOVA (9341 JP): 1H FY03/25 flash update

Consolidated revenue increased by 29.2% YoY to JPY5.1bn, with operating profit growing 25.6% YoY to JPY1.2bn. Medical Platform business revenue...

Shared Research

TOPIX Inclusions: Who Is Ready (Nov 2024)

There are currently 76 names that satisfy all 5 key Segment Transfer requirements based on current data. Another 70 names can satisfy 4 out of 5...

Janaghan Jeyakumar, CFA

TOPIX Inclusions: Who Is Ready (Oct 2024)

The LONGs (Basket A) have outperformed the SHORTs (Basket B) modestly by 0.62% from 7th October to 30th October. On average, the LONGs are down...

Janaghan Jeyakumar, CFA

The TOPIX October FFW Trade - BIG Numbers

The TOPIX Buy/Sell Trade was doing OK through mid-week last week. Then on the 17th it fell hard. That was the day after 'uncertainty" on TCM (570...

Travis Lundy

GENOVA (9341 JP): 70% Rally Over the Last Two Months; Here’s Why Outperformance to Continue

​GENOVA beats Q1FY25 sales and operating profit expectations and is poised to exceed H1FY25 guidance. Steady price-volume growth and potential for...

Tina Banerjee

GENOVA beats Q1FY25 sales and operating profit expectations and is poised to exceed H1FY25 guidance. Steady price-volume growth and potential for...